Cycloalkane derivatives
AssigneeDaiichi Sankyo Company, Limited
InventorsTsuyoshi Shinozuka, Hiroyuki Kobayashi, Sayaka Suzuki, Kyosuke Tanaka, Hiroko Kimoto, Yuki Domon
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic agents and/or preventive agents for pain or therapeutic agents and/or preventive agents for a sodium channel associated disease. The present invention provides compounds represented by the following formula (I) or pharmacologically acceptable salts thereof:
Claims5
A crystalline form of 4-{[(1R,2S)-2-(1-Ethyl-1H-pyrazol-5-yl)cyclopentyl]oxy}-2,3-difluoro-N-(pyrimidin-4-yl)benzenesulfonamide comprising the following peaks in the x-ray powder diffraction pattern:
- Peak No.
- 2θ
- 1
- 7.3
- 2
- 14.6
- 3
- 15.3
- 4
- 16.6
- 5
- 19.4
- 6
- 21.4
- 7
- 22.1
- 8
- 23.4
- 9
- 23.8
- 10
- 29.5
- 11
- 30.6
- .
A crystalline form of 4-{[(1S,2R)-2-(1-Ethyl-1H-pyrazol-5-yl)cyclopentyl]oxy}-2,3-difluoro-N-(pyrimidin-4-yl)benzenesulfonamide comprising the following peaks in the x-ray powder diffraction pattern:
- Peak No.
- 2θ
- 1
- 7.3
- 2
- 14.6
- 3
- 15.3
- 4
- 16.6
- 5
- 19.4
- 6
- 21.4
- 7
- 22.0
- 8
- 23.4
- 9
- 23.8
- 10
- 29.5
- 11
- 30.6
- .
A crystalline form of 5-Chloro-2-fluoro-4-{[(1S,2R)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy}-N-(pyrimidin-4-yl)benzenesulfonamide comprising the following peaks in the x-ray powder diffraction pattern:
- Peak No.
- 2θ
- 1
- 10.0
- 2
- 14.2
- 3
- 18.0
- 4
- 19.6
- 5
- 20.1
- 6
- 20.8
- 7
- 21.2
- 8
- 21.5
- 9
- 24.3
- 10
- 25.6
- 11
- 27.1
- .
A crystalline form of 5-Chloro-2-fluoro-4-{[(1S,2R)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy}-N-(pyrimidin-4-yl)benzenesulfonamide comprising the following peaks in the x-ray powder diffraction pattern:
- Peak No.
- 2θ
- 1
- 9.0
- 2
- 14.8
- 3
- 15.2
- 4
- 17.8
- 5
- 19.3
- 6
- 20.0
- 7
- 20.5
- 8
- 22.3
- 9
- 23.3
- .
A crystalline form of 2-Fluoro-4- {[(1S,2R)-2-(1methyl- 1H-pyrazol-5-yl)cyclopentyl]oxy}-N-(pyrimidin-4-yl)benzenesulfonamide comprising the following peaks in the x-ray powder diffraction pattern:
- Peak No.
- 2θ
- 1
- 7.2
- 2
- 9.3
- 3
- 11.9
- 4
- 14.6
- 5
- 15.6
- 6
- 16.0
- 7
- 18.1
- 8
- 18.9
- 9
- 20.3
- 10
- 21.2
- 11
- 24.8
- .
Dependencies are inferred from the claim text.